Skip to main content

Table 3 Agents targeting cell metabolism for cancer treatment

From: Metabolic reprogramming in macrophage responses

Agent(s)

Target(s)

Effect(s)

Stage of development

Study number(s)

CB-1158

Arginase 1

Inhibits Arginase

Phase I/II

NCT02903914

Phase I

NCT03910530

Phase I/II

NCT03314935

Phase I/II

NCT03837509

Phase I/II

NCT03361228

2DG

Hexokinase

Inhibits glycolysis

Phase I(completed)

NCT00096707

3PO/PFK15

PFKFB3

Inhibits glycolysis

Preclinical(97-100)

 

Shikonin

PKM2

Inhibits PKM2

Preclinical(103-105)

 

DCA

PDK1

Inhibits PDK

Phase II

NCT01386632

Phase I

NCT01111097

Phase II

NCT00540176

GKT137831

NOX4

Inhibits NOX4

Phase II

NCT03226067

CB839

GLS

Inhibits glutamine metabolism

Phase I/II

NCT03875313

Phase I/II

NCT02861300

Phase II

NCT03163667

Others

Others

PX-478

HIF-1α

Inhibits HIF-1α

Phase I

NCT00522652

EZN-2968

HIF-1α

Inhibits HIF-1α

Phase I

NCT01120288

Temsirolimus/ Everolimus

mTOR

Inhibits mTOR

FDA approved

>100

Ridaforolimus

mTOR

Inhibits mTOR

Phase II

NCT00086125

Phase II

NCT00122343

Phase II

NCT00739830

Phase III

NCT00538239

Phase II

NCT00093080

 

(Completed)

Perifosine

AKT

Inhibits AKT

Phase I

NCT02238496